Post-discontinuation Survival in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Pooled Analysis of Prospective Cohort Studies
Discontinuation of ICIs because of a durable tumor response is rare in real-world settings but represents a feasible strategy for patients with advanced NSCLC. Patients in the irAE-CR/PR group had favorable post-ICI discontinuation survival if they received ICI therapy lasting ≥12 months.
Authors
- Hironao Hozumi (ORCID: https://orcid.org/0000-0001-5439-1543)
- Naoki Inui (ORCID: https://orcid.org/0000-0002-4624-7119)
- Mikio Toyoshima (ORCID: https://orcid.org/0000-0002-8349-0142)
- Kazuhiro Asada
- Masato Karayama (ORCID: https://orcid.org/0000-0003-0455-4070)
- Yusuke Kaida (ORCID: https://orcid.org/0000-0003-3991-083X)
- Yuzo Suzuki (ORCID: https://orcid.org/0000-0001-6154-9791)
- Noriyuki Enomoto (ORCID: https://orcid.org/0000-0003-3187-4264)
- Masaki Ikeda (ORCID: https://orcid.org/0000-0003-3861-4246)
- Kazuki Furuhashi (ORCID: https://orcid.org/0000-0003-4079-5509)
- Nao Inami
- Hideki Yasui (ORCID: https://orcid.org/0000-0002-7134-3364)
- Koji Nishimoto (ORCID: https://orcid.org/0000-0002-6515-4276)
- Tomoyuki Fujisawa (ORCID: https://orcid.org/0000-0002-8809-1781)
- Shun Matsuura (ORCID: https://orcid.org/0000-0001-8844-6100)
- Yusuke Inoue (ORCID: https://orcid.org/0000-0001-8075-0597)
- Hiroyuki Matsuda (ORCID: https://orcid.org/0000-0003-2323-0661)
- Masaki Sato (ORCID: https://orcid.org/0000-0002-5444-8607)
- Yasuhiro Ito (ORCID: https://orcid.org/0000-0002-2069-4658)
- Dai Hashimoto
- Takashi Matsui (ORCID: https://orcid.org/0000-0001-9442-9649)
- Yoshihiro Kitahara (ORCID: https://orcid.org/0000-0001-9211-3173)
- Takafumi Suda (ORCID: https://orcid.org/0000-0001-5300-0504)
- Masato Fujii
- Mitsuru Niwa
Institutions
- Hamamatsu University School of Medicine (JP)
- Seirei Mikatabara General Hospital (JP)
- Shizuoka City Shimizu Hospital (JP)
- Takamatsu Red Cross Hospital (JP)
- En Chu Kong Hospital (TW)
- Iwata City Hospital (JP)
- Shizuoka Saiseikai General Hospital (JP)
- Hamamatsu Rosai Hospital (JP)
- Seirei Hamamatsu General Hospital (JP)
- Shizuoka City Hospital (JP)
- Shizuoka General Hospital (JP)
- Shizuoka Red Cross Hospital (JP)
- Fujieda Municipal General Hospital (JP)
- National Hospital Organization (JP)
- Hamamatsu Medical Center (JP)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2025-05-15
- DOI
- https://doi.org/10.1016/j.jtocrr.2025.100847
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05